ReNeuron Group plc Exercise of options, PDMR dealing and TVR (5752Y)
May 09 2019 - 12:05PM
UK Regulatory
TIDMRENE
RNS Number : 5752Y
ReNeuron Group plc
09 May 2019
9 May 2019 AIM: RENE
ReNeuron Group plc
Exercise of options, PDMR dealing and
total voting rights
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based
global leader in the development of cell-based therapeutics,
announces that it has received notices to exercise options from
certain PDMRs of the Company to subscribe for a total of 65,792 new
ordinary shares of 1 pence each in the Company ("Ordinary
Shares").
On 9 May 2019, Sharon Grimster, VP Development and General
Manager Wales, exercised options over 39,960 Ordinary Shares at an
exercise price of 100 pence per share. Subsequently, on 9 May 2019,
Mrs Grimster sold 39,960 Ordinary Shares at a share price of 267
pence.
On 9 May 2019, Dr Randolph Corteling, Head of Research,
exercised options over 25,832 Ordinary Shares at an exercise price
of 100 pence per share. Subsequently, on 9 May 2019, Dr Corteling
sold 25,832 Ordinary Shares at a share price of 267 pence.
Total voting rights
Following the issue of 65,792 Ordinary Shares pursuant to the
exercise of options described above, together with exercise of
options by other staff under its existing blocklisting
arrangements, the Company has 31,799,617 ordinary shares of 1 pence
each in issue, all with voting rights. The Company holds no
ordinary shares in treasury. The above figure of 31,799,617 may be
used by shareholders as the denominator for the calculation by
which they will determine if they are required to notify their
interest in, or a change in their interest in, the Company under
the FCA's Disclosure and Transparency Rules.
S
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison
(NOMAD and Joint Broker)
N+1 Singer +44 (0) 20 7496 3000
Aubrey Powell, Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead clinical-stage candidates are in
development for disability as a result of stroke and for the
blindness-causing disease, retinitis pigmentosa. ReNeuron is also
advancing its proprietary exosome technology platform as a
potential delivery system for drugs that would otherwise be unable
to reach their site of action. ReNeuron's shares are traded on the
London AIM market under the symbol RENE.L. For further information
visit www.reneuron.com.
The notifications set out below are provided in accordance with
the requirements of the EU Market Abuse Regulation and provide
further detail.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sharon Grimster
--------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status VP Development and General Manager
Wales
--------------------------- -----------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------- -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name ReNeuron Group plc
--------------------------- -----------------------------------
b) LEI 2138003TU12CQ5TZO137
--------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial instrument,
type of instrument RENE - GB00BF5G6K95
Identification
code
--------------------------- -----------------------------------
b) Nature of the transaction Exercise of options over ordinary
shares
--------------------------- -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
100 pence 39,960
----------
--------------------------- -----------------------------------
d) Aggregated information N/A
--------------------------- -----------------------------------
e) Date of the transaction 09 May 2019
--------------------------- -----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------- -----------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sharon Grimster
--------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status VP Development and General Manager
Wales
--------------------------- -----------------------------------
b) Initial notification Initial notification
/Amendment
--------------------------- -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name ReNeuron Group plc
--------------------------- -----------------------------------
b) LEI 2138003TU12CQ5TZO137
--------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial instrument,
type of instrument RENE - GB00BF5G6K95
Identification
code
--------------------------- -----------------------------------
b) Nature of the transaction Sale of ordinary shares
--------------------------- -----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
267 pence 39,960
----------
--------------------------- -----------------------------------
d) Aggregated information N/A
--------------------------- -----------------------------------
e) Date of the transaction 09 May 2019
--------------------------- -----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
--------------------------- -----------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Randolph Corteling
---------------------------- ----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Head of Research
---------------------------- ----------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- ----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name ReNeuron Group plc
---------------------------- ----------------------------------
b) LEI 2138003TU12CQ5TZO137
---------------------------- ----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial instrument,
type of instrument RENE - GB00BF5G6K95
Identification
code
---------------------------- ----------------------------------
b) Nature of the transaction Exercise of options over ordinary
shares
---------------------------- ----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
100 pence 25,832
----------
---------------------------- ----------------------------------
d) Aggregated information N/A
---------------------------- ----------------------------------
e) Date of the transaction 09 May 2019
---------------------------- ----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
---------------------------- ----------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Randolph Corteling
---------------------------- ----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Head of Research
---------------------------- ----------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- ----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------
a) Name ReNeuron Group plc
---------------------------- ----------------------------------
b) LEI 2138003TU12CQ5TZO137
---------------------------- ----------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial instrument,
type of instrument RENE - GB00BF5G6K95
Identification
code
---------------------------- ----------------------------------
b) Nature of the transaction Sale of ordinary shares
---------------------------- ----------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
267 pence 25,832
----------
---------------------------- ----------------------------------
d) Aggregated information N/A
---------------------------- ----------------------------------
e) Date of the transaction 09 May 2019
---------------------------- ----------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
---------------------------- ----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEAKSNEEANEFF
(END) Dow Jones Newswires
May 09, 2019 12:05 ET (16:05 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024